EHA 2023 | Analysis of long-term survival in a large APL patient cohort: a Harmony Alliance study

In this presentation, Maria Teresa Voso, MD, of Tor Vergata University, Rome, Italy, discusses a study using data from the HARMONY registry, which analyzed factors associated with long-term survival in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) or ATRA combined with chemotherapy (ATRA+idarubicin, AIDA-based). The HARMONY registry included 1,868 patients with APL diagnosed between 2007 and 2020. Results from the analysis revealed that patients treated with the ATRA-ATO regimen had a ten-year overall survival rate of 92%, compared to 85% in patients treated with the AIDA regimen. The survival advantage was consistent across different risk groups as defined by the Sanz risk-score. Age also played a significant role in survival, with younger patients showing better outcomes. These findings confirm on a large international patient cohort the significant survival advantage of the ATRA-ATO chemotherapy-free regimen for patients with APL, regardless of their risk profile. This press briefing took place at the European Hematology Association (EHA) Congress 2023, held in Frankfurt, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.